CTXR vs. DTIL, INKT, VRCA, PDSB, ELYM, ICCC, ALGS, PRLD, ATNM, and ABVC
Should you be buying Citius Pharmaceuticals stock or one of its competitors? The main competitors of Citius Pharmaceuticals include Precision BioSciences (DTIL), MiNK Therapeutics (INKT), Verrica Pharmaceuticals (VRCA), PDS Biotechnology (PDSB), Eliem Therapeutics (ELYM), ImmuCell (ICCC), Aligos Therapeutics (ALGS), Prelude Therapeutics (PRLD), Actinium Pharmaceuticals (ATNM), and ABVC BioPharma (ABVC). These companies are all part of the "pharmaceutical products" industry.
Citius Pharmaceuticals vs. Its Competitors
Citius Pharmaceuticals (NASDAQ:CTXR) and Precision BioSciences (NASDAQ:DTIL) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.
In the previous week, Citius Pharmaceuticals had 1 more articles in the media than Precision BioSciences. MarketBeat recorded 2 mentions for Citius Pharmaceuticals and 1 mentions for Precision BioSciences. Precision BioSciences' average media sentiment score of 1.87 beat Citius Pharmaceuticals' score of 0.93 indicating that Precision BioSciences is being referred to more favorably in the news media.
Precision BioSciences has higher revenue and earnings than Citius Pharmaceuticals.
16.9% of Citius Pharmaceuticals shares are held by institutional investors. Comparatively, 38.0% of Precision BioSciences shares are held by institutional investors. 10.7% of Citius Pharmaceuticals shares are held by insiders. Comparatively, 4.5% of Precision BioSciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Citius Pharmaceuticals has a net margin of 0.00% compared to Precision BioSciences' net margin of -6,205.79%. Citius Pharmaceuticals' return on equity of -60.03% beat Precision BioSciences' return on equity.
Citius Pharmaceuticals has a beta of 1.19, suggesting that its share price is 19% more volatile than the S&P 500. Comparatively, Precision BioSciences has a beta of 1.52, suggesting that its share price is 52% more volatile than the S&P 500.
Citius Pharmaceuticals presently has a consensus price target of $53.00, suggesting a potential upside of 3,782.78%. Precision BioSciences has a consensus price target of $47.00, suggesting a potential upside of 839.81%. Given Citius Pharmaceuticals' higher probable upside, analysts clearly believe Citius Pharmaceuticals is more favorable than Precision BioSciences.
Summary
Citius Pharmaceuticals and Precision BioSciences tied by winning 6 of the 12 factors compared between the two stocks.
Get Citius Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CTXR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CTXR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Citius Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:CTXR) was last updated on 8/28/2025 by MarketBeat.com Staff
MarketBeat All Access